RxDoctor Payments DataLook up a doctor →

Tina Abraham, DO

Internal Medicine · Pontiac, MINPI 1215376108

Payments from drug & device makers

$833,570in general payments, 2019–2025

Across 1,451 payments — averaging $574.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$436K
  • Regeneron Healthcare Solutions, Inc.$201K
  • Sanofi$108K
  • GSK$49K
  • Amgen$34K
  • Takeda Pharmaceuticals U.S.A., Inc.$729
  • plus $4K from 44 others

What the payments were for

  • Consulting fees$65,4578%
  • Speaking & faculty fees$643,28077%
  • Travel & lodging$89,80911%
  • Food & beverage$34,8094%
  • Education$2150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$833,570 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$48,016
Medicare patients
160
Services billed
3,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab150$559,393
Fasenra PenBenralizumab31$168,521
Trelegy ElliptaFluticasone/Umeclidin/Vilanter123$116,850
XolairOmalizumab33$104,193
TezspireTezepelumab-Ekko26$102,537
NucalaMepolizumab13$42,028
Breo ElliptaFluticasone/Vilanterol44$23,143
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$16,155
SymbicortBudesonide/Formoterol Fumarate36$10,970
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$6,294
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$5,640
DuleraMometasone/Formoterol12$5,209
Advair HfaFluticasone Propion/Salmeterol11$3,958
Azelastine Hcl95$3,621
RyaltrisOlopatadine Hcl/Mometasone12$3,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta$49,330$182,022180 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$436,185$129,66279 claims
MerckDulera$21$5,20912 claims
Hikma Pharmaceuticals USARyaltris$14$3,39112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Pontiac

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →